南财智讯2月26日电，真兰仪表公告，公司于2026年2月26日召开第六届董事会第十八次临时会议和第六 届董事会审计委员会第十一次会议，审议通过了《关于使用部分闲置募集资金（含超募资金）进行现金 管理的议案》；拟使用不超过10.00亿元部分闲置募集资金（含超募资金）进行现金管理，投资于安全 性高、低风险、流动性好的理财产品，包括但不限于大额可转让存单、结构性存款、定期存款及国债逆 回购品种等；使用期限自股东大会审议通过之日起12个月内有效；资金在额度范围内可滚动使用；不会 影响募集资金投资项目进度和公司正常生产经营。 ...

Group 1 - The company, Liaoning He Eye Hospital Group Co., Ltd., has announced a change in the special account for raised funds and the signing of a new tripartite supervision agreement for the management of these funds [1] - The company successfully raised a total of RMB 1,296.25 million through its initial public offering, with a net amount of RMB 1,164.31 million after deducting related expenses [2] - The new special account for the raised funds will be opened at CITIC Bank Shenyang Branch for the "He Eye New Optometry Center Project," and the remaining balance from the previous account will be transferred to this new account [3] Group 2 - The company has signed a new tripartite supervision agreement with CITIC Bank and its sponsor, Zhongyuan Securities, to ensure the proper management of the raised funds [4] - As of February 10, 2026, the amount stored in the new special account is RMB 187.21 million [4] - The tripartite agreement outlines the responsibilities of each party, including the requirement for the company to notify the sponsor of any withdrawals exceeding RMB 50 million or 20% of the net raised funds [7][8]

Core Viewpoint - He Eye Hospital's refractive business is projected to achieve revenue of 135 million yuan in the first half of 2025, reflecting a year-on-year growth of 3.26%, indicating a return to a growth trajectory [1] Group 1: Business Performance - The refractive surgery average selling price (ASP) is on the rise due to an increased proportion of high-value procedures such as femtosecond laser and ICL crystal implantation [1]

Core Viewpoint - He Eye Hospital is implementing a regional development strategy focused on "deepening in Liaoning, radiating nationwide, hierarchical layout, and precise expansion" to build a national three-tier eye health medical service network [1] Group 1: Strategic Focus - The company is concentrating on key urban clusters such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, the Greater Bay Area, and the Yangtze River Delta [1] - The operational model combines direct hospitals with optical franchise collaboration [1]

Group 1: Strategic Planning and Regional Development - The company focuses on a regional development strategy of "deepening in Liaoning, radiating nationwide, hierarchical layout, and precise expansion," targeting core urban clusters such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, Greater Bay Area, and Yangtze River Delta [2][3] - Liaoning serves as the core base and profit pillar, maintaining stable operations and good cash flow, while expanding into provinces like Beijing, Chongqing, Chengdu, and Hainan [3] - The company is optimizing operations by closing underperforming units to enhance overall efficiency without affecting the national layout [3] Group 2: Business Performance and Financial Metrics - Refractive surgery revenue was 239 million CNY in 2023, projected to decrease to 218 million CNY in 2024, a decline of 9.08%, but expected to recover to 135 million CNY in the first half of 2025, a growth of 3.26% [4][5] - Vision care revenue was 387 million CNY in 2023, expected to drop to 365 million CNY in 2024, a decrease of 5.82%, with a projected revenue of 169 million CNY in the first half of 2025, a decline of 4.95% [4][5] - Cataract surgery revenue is forecasted to be 157 million CNY in 2024, down 23.61% year-on-year, with 7.66 million CNY in the first half of 2025, a decrease of 17.67% [6] Group 3: Business Model and Franchise Development - The company employs a light-asset, replicable franchise model for vision care centers, providing brand authorization, standardized operations, and supply chain support [4] - In the first half of 2025, 23 new vision care stores were signed, bringing the total to 53 [5] Group 4: Competitive Landscape and Market Position - The Liaoning eye care market is evolving with increased competition from public institutions and private chains, necessitating a focus on technical and service excellence [7][8] - The company is enhancing its service offerings through a "365 myopia prevention system" and digital health management initiatives [8] Group 5: International Expansion and Investment - The acquisition of 70.65% of Japan's Medical Pathway is a strategic move to integrate advanced regenerative medical technologies and enhance the company's competitive edge in global markets [8] - The investment aims to leverage collaborations with top universities and enhance research and clinical capabilities [8]

上述变更完成后，公司将及时与中信银行沈阳分行营业部、保荐机构中原证 券股份有限公司就设立的募集资金专户签订新的《募集资金三方监管协议》并履 行信息披露义务。公司董事会授权公司财务部负责办理本次募集资金专项账户变 更相关事宜。 证券代码：301103 证券简称：何氏眼科 公告编号：2026-007 辽宁何氏眼科医院集团股份有限公司 关于变更部分募集资金专项账户后重新签订募集资金 三方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、募集资金的基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意辽宁何氏 眼科医院集团股份有限公司首次公开发行股票注册的批复》（证监许可【2022】 126 号）同意注册，辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）首 次公开发行人民币普通股（A 股）3,050 万股，每股面值 1 元，每股发行价格为 人民币 42.5 元，募集资金总额为人民币 129,625.00 万元，扣除与本次发行有关 的费用后募集资金净额为人民币 116,431.13 万元。募集资金已划至公司指定账户。 上述募集资金到 ...

Group 1 - The company, He Eye Hospital, is committed to improving its operations and management while ensuring compliance with regulations [2] - The company aims to explore effective ways and paths for market value management to continuously enhance its intrinsic value [2] - The company seeks to provide long-term stable investment returns for its shareholders [2]

辽宁何氏眼科医院集团股份有限公司 关于与专业投资机构共同投资基金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、对外投资概述 为充分利用专业投资机构在投资并购领域的广泛布局及资源整合能力，促进 公司未来发展，围绕生物技术、医疗健康领域进行产业布局，2026 年 1 月 29 日， 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"或"何氏眼科"）召开第三 届董事会第十六次会议，审议通过了《关于与专业投资机构共同投资基金的议案》， 同意公司拟作为有限合伙人与上海三益浦清管理咨询中心（有限合伙）（以下简 称"三益浦清"、"执行事务合伙人"）、北京中关村科学城三期科技成长股权投资 合伙企业(有限合伙)、上海未来启点私募投资基金合伙企业(有限合伙)、北京海 清本草股权投资中心(有限合伙)、南通投资管理有限公司及其他合伙人（待定）， 共同投资设立上海浦清本草创业投资合伙企业（有限合伙）（以下简称"投资基金" 或"合伙企业"）。 投资基金目标认缴出资总额不低于人民币 100,000 万元，其中公司拟作为有 限合伙人以自有资金认缴出资人民币 8,000 万元。公 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2026-004 辽宁何氏眼科医院集团股份有限公司 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于与专业投资机构共同投资基金的公告》。 本议案已经公司董事会战略与可持续发展委员会事前审议通过。 表决结果：同意 7 票；反对 0 票；弃权 0 票。 （二）审议通过《关于变更募集资金专户的议案》 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第 十六次会议于 2026 年 1 月 29 日在公司会议室以现场及通讯相结合的方式召开， 会议通知已于 2026 年 1 月 23 日以书面文件、电话等方式送达全体董事。会议由 董事长何伟先生主持，应出席董事 7 名，实际出席董事 7 名（其中：何向东以通 讯表决方式出席会议）。公司部分高级管理人员列席了会议。本次会议的召集和 召开符合《中华人民共和国公司法》等法律、法规、规范性文件和《公司章程》 ...

中原证券股份有限公司 关于辽宁何氏眼科医院集团股份有限公司 变更募集资金专户的核查意见 中原证券股份有限公司（以下简称"中原证券"或"保荐机构"）作为辽宁何氏 眼科医院集团股份有限公司（以下简称"何氏眼科""公司"）首次公开发行股票并 在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司 募集资金监管规则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上 市公司自律监管指引第 13 号——保荐业务》等有关规定，对何氏眼科变更募集资 金专户事项进行了审慎核查。核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】126 号）同意注册，公司首 次公开发行人民币普通股（A 股）3,050.00 万股，每股面值 1 元，每股发行价格 为人民币 42.50 元，募集资金总额为人民币 129,625.00 万元，扣除与本次发行有 关的费用后募集资金净额为人民币 116,431.13 万元。募集资金已划至公司指定账 ...